FINDER Flu A&B/SARS-CoV-2 Test
Baebies, Inc. · Decision date Sep 11, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for K261837 on September 11, 2026, clearing the FINDER Flu A&B/SARS-CoV-2 Test from Baebies, Inc. of Durham, North Carolina. The submission was received June 2, 2026, and reviewed under 21 CFR 866.3981, Class II, product code QOF, in the Microbiology panel. The test is an automated, multiplexed, real-time RT-PCR assay run on the FINDER Instrument for qualitative detection and differentiation of SARS-CoV-2, influenza A and influenza B nucleic acid in nasopharyngeal swab specimens from individuals with signs and symptoms of respiratory tract infection.
The cleared change is the instrument user interface: the subject device is FINDER Instrument model 100-000082 with an integrated touchscreen, compared with model 100-000054 with a tablet interface in predicate K252269. The applicant states the underlying technology, performance and risk are unchanged and that the interface change was verified and validated. The decision summary lists no calibration requirement and describes an internal control targeting human RPP30 plus separately sold external controls. Analytical and clinical performance data are not reproduced in the supplied excerpts, so the basis for the equivalence finding beyond the interface change remains unverified here.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Sep 11, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261837
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Baebies, Inc.
- Product code
- QOF
- Decision code
- SESE
- Decision date
- Sep 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents.
- Applicant
- Baebies, Inc.
- Product code
- QOF
- FDA device class
- 2
FDA decision timeline
K261837 received
Application receipt date recorded by FDA.
K261837 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QOF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| GenMark Diagnostics, Inc. | 510(k) clearance | Oct 30, 2026 | FDA | |
Xpert Xpress CoV-2/Flu plusK263333 | Cepheid | 510(k) clearance | Oct 22, 2026 | FDA |
Xpert Xpress CoV-2/Flu plusK263120 | Cepheid | 510(k) clearance | Oct 2, 2026 | FDA |
Xpert Respiratory PanelK261336 | Cepheid | 510(k) clearance | Sep 25, 2026 | FDA |
| Biofire Diagnostics | 510(k) clearance | Sep 22, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Baebies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Durham, NC
Sources and methodology
- Original FDA record: K261837
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

